$MRNS
MARINUS PHARMACEUTICALS, INC. Stock $mrns

$mrns Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000155837022016604 Filed on November 07, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q4
Revenue	$7.162M	$2.340M	$1.520M
YoY Change	371.18%	-76.86%	-1.94%
Cost Of Revenue	$292.0K	$48.00K
YoY Change		-96.75%
Gross Profit	$6.870M	$2.292M
YoY Change		-73.46%
Gross Profit Margin	95.92%	97.95%
Selling, General & Admin	$14.66M	$13.39M	$10.62M
YoY Change	38.0%	41.65%	76.74%
% of Gross Profit	213.36%	584.16%
Research & Development	$21.42M	$19.00M	$18.01M
YoY Change	18.93%	3.54%	38.14%
% of Gross Profit	311.85%	829.06%
Depreciation & Amortization	$82.00K	$158.0K	$93.00K
YoY Change	-11.83%	73.63%	3.33%
% of Gross Profit	1.19%	6.89%
Operating Expenses	$36.08M	$32.39M	$28.64M
YoY Change	26.0%	76.49%	50.32%
Operating Profit	-$29.21M	-$30.10M
YoY Change		57.02%
Interest Expense	-$1.946M	$2.634M	-$1.530M
YoY Change	27.19%	288.5%	-3925.0%
% of Operating Profit
Other Income/Expense, Net	-$717.0K	-$114.0K	$541.0K
YoY Change	-232.53%	-135.29%	-5510.0%
Pretax Income	-$32.67M	$75.04M	-$28.31M
YoY Change	15.44%	-484.69%	62.02%
Income Tax	$1.637M	$1.752M
% Of Pretax Income		2.33%
Net Earnings	-$33.98M	$73.29M	-$28.31M
YoY Change	20.04%	-475.71%	62.02%
Net Earnings / Revenue	-474.39%	3132.05%	-1862.17%
Basic Earnings Per Share		$1.93
Diluted Earnings Per Share	-$0.75	$1.89	-$769.4K
COMMON SHARES
Basic Shares Outstanding	37.20M	37.20M	36.77M
Diluted Shares Outstanding		37.91M

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$240.6M	$168.2M	$122.9M
YoY Change	95.69%	15.95%	-12.2%
Cash & Equivalents	$240.6M	$168.2M	$122.9M
Short-Term Investments			$0.00
Other Short-Term Assets	$5.402M	$5.255M	$5.565M
YoY Change	-2.93%	8.17%	20.98%
Inventory	$77.00K	$104.0K	$0.00
Prepaid Expenses
Receivables	$6.348M	$3.398M	$2.629M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$252.4M	$177.0M	$131.7M
YoY Change	91.66%	15.32%	-9.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.236M	$5.520M	$2.499M
YoY Change	69.51%	108.3%	28.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.904M	$2.315M	$2.663M
YoY Change	9.05%	-15.26%	18.36%
Total Long-Term Assets	$7.140M	$7.835M	$5.162M
YoY Change	38.32%	45.58%	23.05%
TOTAL ASSETS
Total Short-Term Assets	$252.4M	$177.0M	$131.7M
Total Long-Term Assets	$7.140M	$7.835M	$5.162M
Total Assets	$259.5M	$184.8M	$136.8M
YoY Change	89.65%	16.35%	-9.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.461M	$1.622M	$3.126M
YoY Change	42.71%	134.05%	41.38%
Accrued Expenses	$19.54M	$19.43M	$16.21M
YoY Change	20.54%	28.2%	90.27%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$25.02M	$21.05M	$40.57M
YoY Change	-38.33%	-44.13%	278.1%
LONG-TERM LIABILITIES
Long-Term Debt	$71.02M	$70.78M	$40.81M
YoY Change	74.03%	74.43%
Other Long-Term Liabilities	$47.48M	$11.01M	$1.979M
YoY Change	2299.34%	418.22%	-20.84%
Total Long-Term Liabilities	$118.5M	$81.79M	$42.79M
YoY Change	176.95%	91.53%	1611.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$25.02M	$21.05M	$40.57M
Total Long-Term Liabilities	$118.5M	$81.79M	$42.79M
Total Liabilities	$143.5M	$102.8M	$83.35M
YoY Change	72.18%	27.94%	528.47%
SHAREHOLDERS EQUITY
Retained Earnings	-$430.5M	-$396.2M	-$410.7M
YoY Change	4.82%	3.61%	31.67%
Common Stock	$50.00K	$37.00K	$37.00K
YoY Change	35.14%	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares			$7.307K
Shareholders Equity	$116.0M	$82.00M	$53.49M
YoY Change
Total Liabilities & Shareholders Equity	$259.5M	$184.8M	$136.8M
YoY Change	89.65%	16.35%	-9.05%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q4
OPERATING ACTIVITIES
Net Income	-$33.98M	$73.29M	-$28.31M
YoY Change	20.04%	-475.71%	62.02%
Depreciation, Depletion And Amortization	$82.00K	$158.0K	$93.00K
YoY Change	-11.83%	73.63%	3.33%
Cash From Operating Activities	-$21.91M	-$29.64M	-$21.75M
YoY Change	0.75%	-648.68%	32.62%
INVESTING ACTIVITIES
Capital Expenditures	$92.00K	-$1.261M	-$721.0K
YoY Change	-112.76%	44.61%
Acquisitions
YoY Change
Other Investing Activities	$171.0K	$107.4M	$0.00
YoY Change			-100.0%
Cash From Investing Activities	$79.00K	$106.1M	-$721.0K
YoY Change	-110.96%	-12269.04%	-129.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	94.14M	-546.0K	297.0K
YoY Change	31595.96%	-101.94%	-99.54%
NET CHANGE
Cash From Operating Activities	-21.91M	-29.64M	-21.75M
Cash From Investing Activities	79.00K	106.1M	-721.0K
Cash From Financing Activities	94.14M	-546.0K	297.0K
Net Change In Cash	72.30M	75.92M	-22.17M
YoY Change	-426.07%	132.84%	-143.33%
FREE CASH FLOW
Cash From Operating Activities	-$21.91M	-$29.64M	-$21.75M
Capital Expenditures	$92.00K	-$1.261M	-$721.0K
Free Cash Flow	-$22.01M	-$28.38M	-$21.03M
YoY Change	4.65%	-552.33%	28.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	1018000
	mrns	Increase Decrease In Prepaid Expense And Other Assets Noncurrent Assets Inventory And Accounts Receivable IncreaseDecreaseInPrepaidExpenseAndOtherAssetsNoncurrentAssetsInventoryAndAccountsReceivable	2313000
	mrns	Increase Decrease In Prepaid Expense And Other Assets Noncurrent Assets Inventory And Accounts Receivable IncreaseDecreaseInPrepaidExpenseAndOtherAssetsNoncurrentAssetsInventoryAndAccountsReceivable	453000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1052000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4511000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-90972000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33727000
	mrns	Proceeds From Sale Of Priority Review Voucher ProceedsFromSaleOfPriorityReviewVoucher	107375000
	us-gaap	Depreciation Depreciation	336000
	us-gaap	Depreciation Depreciation	262000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1133000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	319000
	us-gaap	Share Based Compensation ShareBasedCompensation	11091000
	us-gaap	Share Based Compensation ShareBasedCompensation	10867000
	mrns	Increase Decrease Amortization Of Net Contract Asset Liability IncreaseDecreaseAmortizationOfNetContractAssetLiability	1000000
	mrns	Increase Decrease Amortization Of Net Contract Asset Liability IncreaseDecreaseAmortizationOfNetContractAssetLiability	41000
	mrns	Non Cash Operating Lease Expense Operating Activities NonCashOperatingLeaseExpenseOperatingActivities	194000
	mrns	Non Cash Operating Lease Expense Operating Activities NonCashOperatingLeaseExpenseOperatingActivities	232000
	mrns	Interest Expense Income On Lease Liabilities InterestExpenseIncomeOnLeaseLiabilities	252000
	mrns	Interest Expense Income On Lease Liabilities InterestExpenseIncomeOnLeaseLiabilities	237000
	mrns	Fixed Assets Written Off FixedAssetsWrittenOff	169000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1169000
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-930000
	mrns	Increase Decrease In Contract With Customer Refund Liability IncreaseDecreaseInContractWithCustomerRefundLiability	-22163000
	mrns	Increase Decrease In Contract With Customer Refund Liability IncreaseDecreaseInContractWithCustomerRefundLiability	21828000
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-11057000
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	1474000
	mrns	Payments For Deposit And Property And Equipment PaymentsForDepositAndPropertyAndEquipment	1329000
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	1682000
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	839000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	105693000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-694000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1763000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	902000
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	28838000
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	40259000
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	148000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	30601000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	41013000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6592000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	122927000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	138509000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	168249000
	dei	Entity File Number EntityFileNumber	001-36576
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAccruedLiabilitiesNoncurrent
	dei	Entity Central Index Key EntityCentralIndexKey	0001267813
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue
CY2021Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue
CY2022Q3	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAccruedLiabilitiesNoncurrent
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity Registrant Name EntityRegistrantName	MARINUS PHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-0198082
	dei	Entity Address Address Line1 EntityAddressAddressLine1	5 Radnor Corporate Center, Suite 500
	dei	Entity Address Address Line2 EntityAddressAddressLine2	100 Matsonford Rd
	dei	Entity Address City Or Town EntityAddressCityOrTown	Radnor
	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19087
	dei	City Area Code CityAreaCode	484
	dei	Local Phone Number LocalPhoneNumber	801-4670
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	MRNS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37196644
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	168249000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	122927000
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3398000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2629000
CY2022Q3	us-gaap	Inventory Net InventoryNet	104000
CY2021Q4	mrns	Contract With Customer Asset Liability Net ContractWithCustomerAssetLiabilityNet	557000
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5255000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5565000
CY2022Q3	us-gaap	Assets Current AssetsCurrent	177006000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	131678000
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5520000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2499000
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2315000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2663000
CY2022Q3	us-gaap	Assets Assets	184841000
CY2021Q4	us-gaap	Assets Assets	136840000
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1622000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3126000
CY2021Q4	mrns	Upfront Payment Refund Liability UpfrontPaymentRefundLiability	21233000
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19428000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16207000
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	21050000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40566000
CY2022Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	70780000
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	40809000
CY2022Q3	mrns	Contract With Customer Contract Liability Net Of Contract Asset ContractWithCustomerContractLiabilityNetOfContractAsset	9499000
CY2022Q3	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	1508000
CY2021Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	1979000
CY2022Q3	us-gaap	Liabilities Liabilities	102837000
CY2021Q4	us-gaap	Liabilities Liabilities	83354000
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	4043000
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	4302000
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37203951
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37196644
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36797561
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36790254
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	37000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	37000
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	474133000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	459852000
CY2022Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	7307
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	7307
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-396209000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-410705000
CY2021Q3	us-gaap	Interest Expense InterestExpense	678000
	us-gaap	Interest Expense InterestExpense	6982000
	us-gaap	Interest Expense InterestExpense	1029000
CY2022Q3	mrns	Gain Loss On Sale Of Priority Review Voucher Net GainLossOnSaleOfPriorityReviewVoucherNet	107375000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	82004000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	53486000
CY2022Q3	us-gaap	Interest Expense InterestExpense	2634000
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	184841000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	136840000
CY2022Q3	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	1785000
CY2021Q3	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	1127000
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	5088000
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	4838000
CY2022Q3	us-gaap	Revenues Revenues	2340000
CY2021Q3	us-gaap	Revenues Revenues	10114000
	us-gaap	Revenues Revenues	18316000
	us-gaap	Revenues Revenues	13825000
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19002000
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18353000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	58488000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	55506000
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13389000
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9452000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	42187000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26656000
	mrns	Cost Of License Fees CostOfLicenseFees	1169000
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	32439000
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	29283000
	us-gaap	Costs And Expenses CostsAndExpenses	101892000
	us-gaap	Costs And Expenses CostsAndExpenses	83640000
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-30099000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-19169000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-83576000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-69815000
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	514000
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	17000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	610000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	57000
	mrns	Gain Loss On Sale Of Priority Review Voucher Net GainLossOnSaleOfPriorityReviewVoucherNet	107375000
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-114000
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	323000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1179000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	316000
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	75042000
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19507000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	16248000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-70471000
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1752000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1752000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	73290000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-19507000
	us-gaap	Net Income Loss NetIncomeLoss	14496000
	us-gaap	Net Income Loss NetIncomeLoss	-70471000
	mrns	Fixed Assets Written Off FixedAssetsWrittenOff	169000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1169000
CY2022Q3	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	1656000
	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	336000
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	71634000
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19507000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	14160000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-70471000
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.93
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.38
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.92
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.89
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.53
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.37
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.92
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37202269
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36744591
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37084060
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36667472
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37910511
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36744591
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38393754
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36667472
	us-gaap	Profit Loss ProfitLoss	14496000
	us-gaap	Profit Loss ProfitLoss	-70471000
	mrns	Gain Loss On Sale Of Priority Review Voucher Net GainLossOnSaleOfPriorityReviewVoucherNet	107375000
	us-gaap	Depreciation Depreciation	336000
	us-gaap	Depreciation Depreciation	262000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1133000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	319000
	us-gaap	Share Based Compensation ShareBasedCompensation	11091000
	us-gaap	Share Based Compensation ShareBasedCompensation	10867000
	mrns	Increase Decrease Amortization Of Net Contract Asset Liability IncreaseDecreaseAmortizationOfNetContractAssetLiability	1000000
	mrns	Increase Decrease Amortization Of Net Contract Asset Liability IncreaseDecreaseAmortizationOfNetContractAssetLiability	41000
	mrns	Non Cash Operating Lease Expense Operating Activities NonCashOperatingLeaseExpenseOperatingActivities	194000
	mrns	Non Cash Operating Lease Expense Operating Activities NonCashOperatingLeaseExpenseOperatingActivities	232000
	mrns	Interest Expense Income On Lease Liabilities InterestExpenseIncomeOnLeaseLiabilities	252000
	mrns	Interest Expense Income On Lease Liabilities InterestExpenseIncomeOnLeaseLiabilities	237000
	mrns	Increase Decrease In Contract With Customer Refund Liability IncreaseDecreaseInContractWithCustomerRefundLiability	21828000
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-11057000
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	1018000
	mrns	Increase Decrease In Prepaid Expense And Other Assets Noncurrent Assets Inventory And Accounts Receivable IncreaseDecreaseInPrepaidExpenseAndOtherAssetsNoncurrentAssetsInventoryAndAccountsReceivable	2313000
	mrns	Increase Decrease In Prepaid Expense And Other Assets Noncurrent Assets Inventory And Accounts Receivable IncreaseDecreaseInPrepaidExpenseAndOtherAssetsNoncurrentAssetsInventoryAndAccountsReceivable	453000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-90972000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33727000
	mrns	Proceeds From Sale Of Priority Review Voucher ProceedsFromSaleOfPriorityReviewVoucher	107375000
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	1682000
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	839000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	105693000
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	244000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-27141000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-694000
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	28838000
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	40259000
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	148000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	30601000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	41013000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	45322000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6592000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	122927000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	138509000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	168249000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	145101000
	mrns	Contractual Exit Fee Included In Notes Payable ContractualExitFeeIncludedInNotesPayable	900000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	107000
	mrns	Property And Equipment In Deposits Placed In Service PropertyAndEquipmentInDepositsPlacedInService	1665000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	137199000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5035000
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	244000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-27141000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	115334000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2991000
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	557000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-23823000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	95059000
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2841000
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	101000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-19507000
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	78494000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	53486000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3379000
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1733000
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1168000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-19361000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	40405000
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3817000
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-39433000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	4803000
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3895000
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	16000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	73290000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	82004000
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-396200000
	mrns	Government Cost Share Amount GovernmentCostShareAmount	12300000
CY2022Q3	mrns	Proceeds From Sale Of Priority Review Voucher ProceedsFromSaleOfPriorityReviewVoucher	107400000
	mrns	Number Of Customers NumberOfCustomers	1
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	115334000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2991000
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	557000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-23823000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	95059000
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2841000
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	101000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-19507000
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	78494000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	53486000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3379000
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1733000
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1168000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-19361000
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-39433000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	4803000
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3895000
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	16000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	73290000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	82004000
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-396200000
	mrns	Government Cost Share Amount GovernmentCostShareAmount	12300000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from such estimates.</p>
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0
	mrns	Trade Receivable Payment Term TradeReceivablePaymentTerm	P30D
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from such estimates.</p>
	mrns	Number Of Customers NumberOfCustomers	1
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0
	mrns	Trade Receivable Payment Term TradeReceivablePaymentTerm	P30D
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	104000
CY2022Q3	us-gaap	Inventory Net InventoryNet	104000
CY2021Q4	us-gaap	Inventory Net InventoryNet	0
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37202269
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36744591
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37084060
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5830000
CY2022Q3	mrns	Clinical Trials And Drug Development Current ClinicalTrialsAndDrugDevelopmentCurrent	7601000
CY2021Q4	mrns	Clinical Trials And Drug Development Current ClinicalTrialsAndDrugDevelopmentCurrent	8217000
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	104000
CY2022Q3	us-gaap	Inventory Net InventoryNet	104000
CY2021Q4	us-gaap	Inventory Net InventoryNet	0
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6466000
CY2022Q3	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	1656000
	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	336000
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	71634000
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19507000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	14160000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-70471000
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6466000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5830000
CY2022Q3	mrns	Clinical Trials And Drug Development Current ClinicalTrialsAndDrugDevelopmentCurrent	7601000
CY2021Q4	mrns	Clinical Trials And Drug Development Current ClinicalTrialsAndDrugDevelopmentCurrent	8217000
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1066000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1311000
CY2022Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1752000
CY2022Q3	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1207000
CY2022Q3	mrns	Lease Liability Short Term LeaseLiabilityShortTerm	616000
CY2021Q4	mrns	Lease Liability Short Term LeaseLiabilityShortTerm	556000
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	720000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	293000
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19428000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16207000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	73290000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-19507000
	us-gaap	Net Income Loss NetIncomeLoss	14496000
	us-gaap	Net Income Loss NetIncomeLoss	-70471000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36667472
CY2022Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	708242
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1309694
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37910511
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36744591
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38393754
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36667472
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.93
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.38
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1066000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1311000
CY2022Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1752000
CY2022Q3	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1207000
CY2022Q3	mrns	Lease Liability Short Term LeaseLiabilityShortTerm	616000
CY2021Q4	mrns	Lease Liability Short Term LeaseLiabilityShortTerm	556000
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	720000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	293000
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19428000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16207000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	73290000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-19507000
	us-gaap	Net Income Loss NetIncomeLoss	14496000
	us-gaap	Net Income Loss NetIncomeLoss	-70471000
CY2022Q3	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	1656000
	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	336000
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	71634000
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19507000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	14160000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-70471000
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37202269
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36744591
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37084060
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36667472
CY2022Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	708242
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1309694
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37910511
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36744591
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38393754
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36667472
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.93
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.38
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.92
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.89
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.53
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.37
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.92
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4735841
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.92
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.89
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.92
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4735841
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5577768
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4566687
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5577768
CY2022Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	860000
CY2022Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P78M
CY2022Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P60M
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P36M
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1400000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1700000
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2100000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2500000
CY2022Q3	us-gaap	Lease Cost LeaseCost	100000
CY2021Q3	us-gaap	Lease Cost LeaseCost	200000
	us-gaap	Lease Cost LeaseCost	400000
	us-gaap	Lease Cost LeaseCost	500000
CY2022Q3	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.110
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2124000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	203000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	823000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	840000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	642000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2508000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	384000
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2124000
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	616000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4566687
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5577768
CY2022Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	860000
CY2022Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P78M
CY2022Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P60M
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P36M
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2100000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2500000
CY2022Q3	us-gaap	Lease Cost LeaseCost	100000
CY2021Q3	us-gaap	Lease Cost LeaseCost	200000
	us-gaap	Lease Cost LeaseCost	400000
	us-gaap	Lease Cost LeaseCost	500000
CY2022Q3	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.110
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	823000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	840000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	384000
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2124000
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	616000
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1508000
CY2022Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	75000000
CY2022Q3	mrns	Contractual Term Loan Exit Fees ContractualTermLoanExitFees	1500000
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	5720000
CY2022Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	70780000
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1508000
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2124000
CY2022Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	75000000
CY2022Q3	mrns	Contractual Term Loan Exit Fees ContractualTermLoanExitFees	1500000
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	5720000
CY2022Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	70780000
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	11250000
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	15000000
CY2022Q3	mrns	Long Term Debt Maturities Repayments Of Principal In Year Four And Thereafter LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter	48750000
CY2022Q3	us-gaap	Long Term Debt LongTermDebt	75000000
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	6624000
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	7181000
CY2021Q4	mrns	Contract With Customer Asset Liability Net ContractWithCustomerAssetLiabilityNet	557000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1800000
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	11250000
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	15000000
CY2022Q3	mrns	Long Term Debt Maturities Repayments Of Principal In Year Four And Thereafter LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter	48750000
CY2022Q3	us-gaap	Long Term Debt LongTermDebt	75000000
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	6624000
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	7181000
CY2021Q4	mrns	Contract With Customer Asset Liability Net ContractWithCustomerAssetLiabilityNet	557000
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	15114000
CY2022Q3	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	5615000
CY2022Q3	mrns	Contract With Customer Contract Liability Net Of Contract Asset ContractWithCustomerContractLiabilityNetOfContractAsset	9499000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1800000

Files In Submission

Name	View Source	Status
0001558370-22-016604-index-headers.html	Edgar Link	pending
0001558370-22-016604-index.html	Edgar Link	pending
0001558370-22-016604.txt	Edgar Link	pending
0001558370-22-016604-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mrns-20220930.xsd	Edgar Link	pending
mrns-20220930x10q.htm	Edgar Link	pending
mrns-20220930x10q004.jpg	Edgar Link	pending
mrns-20220930x10q007.jpg	Edgar Link	pending
mrns-20220930xex10d3.htm	Edgar Link	pending
mrns-20220930xex10d4.htm	Edgar Link	pending
mrns-20220930xex10d5.htm	Edgar Link	pending
mrns-20220930xex31d1.htm	Edgar Link	pending
mrns-20220930xex31d2.htm	Edgar Link	pending
mrns-20220930xex32d1.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
mrns-20220930_def.xml	Edgar Link	unprocessable
mrns-20220930_pre.xml	Edgar Link	unprocessable
mrns-20220930_lab.xml	Edgar Link	unprocessable
mrns-20220930x10q_htm.xml	Edgar Link	completed
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mrns-20220930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MRNS
MARINUS PHARMACEUTICALS, INC. Stock $mrns

2022 Q4 Form 10-Q Financial Statement

#000155837022016604 Filed on November 07, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRNS MARINUS PHARMACEUTICALS, INC. Stock $mrns

2022 Q4 Form 10-Q Financial Statement

#000155837022016604 Filed on November 07, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRNS
MARINUS PHARMACEUTICALS, INC. Stock $mrns